EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NovaBay Pharmaceuticals's Enterprise Value is $3.45 Mil.
NovaBay Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.81 Mil. Therefore, NovaBay Pharmaceuticals's EV-to-FCF for today is -0.72.
The historical rank and industry rank for NovaBay Pharmaceuticals's EV-to-FCF or its related term are showing as below:
NBY'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.34 Med: -1.73 Max: -0.12
Current: -0.72
During the past 13 years, the highest EV-to-FCF of NovaBay Pharmaceuticals was -0.12. The lowest was -17.34. And the median was -1.73.
NBY's EV-to-FCF is ranked worse than 100% of 416
companies
in the Biotechnology industry
Industry Median: 4.095
vs NBY: -0.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NovaBay Pharmaceuticals's EV-to-FCF
For the Biotechnology subindustry, NovaBay Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovaBay Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NovaBay Pharmaceuticals's EV-to-FCF falls into.
NovaBay Pharmaceuticals's current Enterprise Value is $3.45 Mil.
NovaBay Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NovaBay Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
NovaBay Pharmaceuticals's share price for today is $0.605.
NovaBay Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.796.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NovaBay Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBY has been successfully added to your 